Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer
- 1.6k Downloads
Symptoms of depression and anxiety are common in patients with lung cancer and may produce an impact on both health-related quality of life (HRQL) and survival. The aim of the present study was to evaluate the association of depression and anxiety on HRQL, treatment adherence, and prognosis in patients with non-small cell lung cancer (NSCLC).
This is a prospective study of patients with stage IIIB or IV NSCLC. Depression and anxiety were measured using the hospital anxiety and depression scale, the International Neuropsychiatric Interview, and the HRQL with the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Instruments were applied before treatment and repeated at 3 and 6 months. Lack of treatment adherence was considered as patients who stopped going to their consultation appointments.
A total of 82 patients were included. At the initial evaluation, depression and anxiety were found in 32.9 and 34.1 % of patients, respectively. Depression was associated with feminine gender (p = 0.034) and poor performance status (p = 0.048). Depression and anxiety showed an association with HRQL. Patients with depression showed median overall survival of 6.8 months, whereas that for nondepressed patients was 14 months (hazard ratio [HR], 1.9; 95 % confidence interval (95 % CI), 1.03–3.7; p = 0.042). The 58 % of patients with depression had poor treatment adherence versus 42 % of patients without depression (p = 0.004).
Depression and anxiety were present in one-third of patients with recently diagnosed NSCLC. Depression and anxiety were associated with decreased HRQL scales, and depression was independently associated with treatment adherence and with poor prognosis.
KeywordsDepression Overall Survival Treatment Adherence Advanced NSCLC Karnofsky Performance Status
This project was supported partially by Instituto Nacional de Cancerología (INCan) and CONACYT (115574).
Conflict of interest
The authors have nothing to disclose.
- 1.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed 15 April 2012.
- 4.D’Addario G, Felip E, ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:39–40.Google Scholar
- 11.Pirl WF. Depresión, ansiedad y fatiga. In: Chabner BA, Lynch TJ, Longo DL, editors. Harrison’s Manual de Oncología. Mexico City: McGraw-Hill de Mexico; 2011. p. 190–6.Google Scholar
- 17.Fayers PM, Machin D. Quality of life: assessment, analysis and interpretation. 2nd ed. New York: Wiley; 2007.Google Scholar
- 22.López-Alvarenga JC, Vázquez-Velázquez V, Arcila-Martínez D, Sierra-Ovando AE, González-Barranco J, Salín-Pascual RJ. Exactitud y utilidad diagnóstica del Hospital Anxiety and Depression Scale (HAD) en una muestra de sujetos obesos mexicanos [Accuracy and diagnostic utility of the Hospital Anxiety and Depression Scale (HAD) in a sample of obese Mexican patients]. Rev Invest Clin. 2002;54:403–9.PubMedGoogle Scholar
- 24.Arrieta O, Núñez-Valencia C, Reynoso-Erazo L, Alvarado S, Flores-Estrada D, Angulo LP, et al. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer. 2012;77:205–11.PubMedCrossRefGoogle Scholar
- 27.Arrarás JI, Pruja E, Marcos M, Tejedor M, Illarramendi JJ, Vera R, et al. El cuestionario de calidad de vida para cáncer de pulmón de la EORTC QLQ-LC13. Estudio de validación para nuestro país. Oncologia. 2000;23:127–34.Google Scholar
- 28.Greene FL, Balch CM, Fleming ID, Fritz AG, Haller DG, Morrow M, et al. (eds). AJCC cancer staging handbook from the AJCC cancer staging manual. 6th ed. New York: Springer; 2002.Google Scholar